Gbm Protein — Glioblastoma Multiforme is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Glioblastoma Multiforme (GBM) is the most aggressive and common primary brain tumor in adults, classified as World Health Organization (WHO) Grade IV glioma[@louis2016]. Despite being a malignancy rather than a neurodegenerative disease, GBM shares several molecular pathways and therapeutic targets with neurodegenerative conditions, making it relevant to neuro-oncology research.
GBM arises from glial cells ([astrocytes](/entities/astrocytes) or oligodendrocyte precursor cells) and is characterized by rapid growth, invasive behavior, and poor prognosis. The median survival with standard treatment (surgery followed by radiotherapy and temozolomide chemotherapy) is approximately 15 months[@stupp2009].
Molecular Biology
Genetic Alterations
GBM is characterized by several key genetic alterations:
EGFR Amplification: Epidermal Growth Factor Receptor gene amplification occurs in ~40% of primary GBM cases, leading to constitutive activation of proliferative signaling pathways[@furnari2007]
PTEN Loss: Phosphatase and tensin homolog deletion is found in ~30-40% of cases
TP53 Mutations: Tumor protein p53 mutations are common, particularly in secondary GBM
IDH1/IDH2 Mutations: Isocitrate dehydrogenase mutations are more common in secondary GBM and carry better prognosis
AI and Machine Learning: Predicting treatment response
Background
The study of Gbm Protein — Glioblastoma Multiforme has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Louis DN, et al, WHO Classification of Tumors of the Central Nervous System (2016)](https://pubmed.ncbi.nlm.nih.gov/27157931/)
[Stupp R, et al, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study (2009)](https://pubmed.ncbi.nlm.nih.gov/19269895/)
[Furnari FB, et al, Malignant astrocytic glioma: genetics, biology, and paths to treatment (2007)](https://pubmed.ncbi.nlm.nih.gov/17974913/)